Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autophagy-Related Indication Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RUBCN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RUBCN Recombinant Protein (RUN / Cysteine-Rich Domain) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for PPI assays. |
View RUBCN Products |
| Gene Delivery | RUBCN Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and autophagic flux monitoring. |
View RUBCN Products |
| Benchmark Ab | Anti-RUBCN Recombinant Antibody High-affinity positive control for Western Blot, IP, and Immunofluorescence assays. |
View RUBCN Products |
| Validator | RUBCN siRNA Set For target knockdown verification in cell-based autophagy rescue studies. |
View RUBCN Products |
| Related Target A | BECN1 (Beclin 1) Direct interaction partner of RUBCN; essential component of the Class III PI3K complex regulating autophagy. |
View BECN1 Products |
| Related Target B | ATG14 Competes with RUBCN for Beclin 1 binding; critical switch between autophagy activation and inhibition. |
View ATG14 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) screening (RUBCN-BECN1) | Highly stable, sequence-verified recombinant domains expressed with native-like folding. |
| Autophagic flux quantification in cell lines | High-titer Lentivirus particles for stable expression of RUBCN and fluorescent autophagy markers. |
| Lack of Controls | Sequence-verified Benchmark Antibodies and validated positive controls included. |
| False Positives | Validated siRNA sets included for specific target knockdown validation. |
Live RUBCN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RUBCN therapeutics is intensifying, with major players shifting focus from traditional systemic modulators to targeted intracellular protein-protein interaction (PPI) inhibitors and genetic medicines. As first-generation autophagy-targeting therapies reach the clinic, the next wave of R&D is targeting RUBCN to reverse age-related autophagic decline and treat metabolic diseases like NASH/MASH and neurodegeneration.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Spin-offs, Biotech | NASH/MASH, Neurodegeneration | Selectivity Assay (Need recombinant RUBCN vs ATG14/UVRAG complexes) |
| RNA Therapeutics (siRNA/ASO) | Alnylam, Ionis Partners | Age-related Liver Disease | Knockdown Validation (Need validated siRNA and high-affinity qPCR/WB controls) |
| Gene Therapy / Overexpression | Gene Therapy Biotechs | Immune-oncology (LAP pathway) | Transduction Efficiency (Need high-titer Lentivirus for stable cell lines) |